RT Journal Article SR Electronic T1 Effective Treatment for Malignant Pleural Effusion and Ascites with Combined Therapy of Bevacizumab and Cisplatin JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1313 OP 1318 VO 36 IS 3 A1 LIXIN JIANG A1 PENG LI A1 ZHAOHUA GONG A1 BAOHONG HU A1 JING MA A1 JIAHUI WANG A1 HONGJIN CHU A1 LIANGMING ZHANG A1 PING SUN A1 JIAN CHEN YR 2016 UL http://ar.iiarjournals.org/content/36/3/1313.abstract AB Objective: To record the efficacy and toxicity of combining bevacizumab with cisplatin in treating malignant pleural effusion and ascites through intrapleural and intraperitoneal infusion. Patients and Methods: Forty-three patients were admitted to the Oncology Department of Yantai Yuhuangding Hospital with confirmed malignant effusion since January, 2011. Twenty of them received intrapleural and intraperitoneal perfusion of 200 mg bevacizumab plus 60 mg cisplatin every three weeks, and 23 patients received 60 mg cisplatin alone after draining effusion as much as possible. Reduction of effusion was determined by type-B ultrasonography. Results: The complete remission rate and effective rate of bevacizumab group was superior to that of the cisplatin group. The quality of life recovery rate of bevacizumab group was superior to that of the cisplatin group. The anhelation and abdominal distention of bevacizumab group was significantly improved. There was no significant difference in level III/IV toxicities and adverse effects between two groups. Conclusion: Bevacizumab significantly improved the objective response rate and quality of life of patients with malignant pleural effusion and ascites, while not causing notable adverse events.